Table 3 Severe (grade 3 and 4) haematologic and nonhaematologic toxicity

From: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

 

Grade 3 and 4 (WHO)

 

IG

G

 
 

n =60

n =70

 
 

n (%)

n (%)

P -value

Anemia

3 (5)

3 (4.3)

NS

Neutropenia

16 (26.7)

11 (15.7)

0.125

Thrombocytopenia

3 (5)

—

0.028

Nausea

1 (1.7)

2 (2.9)

NS

Vomiting

1 (1.7)

1 (1.4)

NS

Diarrhea

2 (3.3)

2 (2.9)

NS

Asthenia

—

4 (5.7)

—

Influenza-like syndrome

2 (3.3)

—

 
Back to article page